Nurix Therapeutics announces extension of collaboration with Gilead

Nurix Therapeutics (NRIX) announced that Gilead Sciences (GILD) has elected to extend the research term of the companies’ ongoing collaboration, originally established in 2019, by an additional two years. “Gilead’s extension of the research period of this agreement is a testament to the productivity of our collaboration to date. Most importantly, it increases the opportunity for additional clinical candidates and associated milestones to emerge from our work together with the Gilead team,” said Gwenn M. Hansen, Ph.D., chief scientific officer of Nurix. “Progress in the collaboration has already yielded the first development candidate GS-6791, a potent, selective, oral IRAK4 degrader that has potential applications in the treatment of rheumatoid arthritis and other inflammatory diseases, which Gilead licensed in March 2023. With this extended research term, we aim to deliver multiple additional clinical candidates to advance a portfolio of novel targeted protein degrader therapies with Gilead.” Under the collaboration agreement, Nurix is deploying its proprietary drug discovery platform to identify novel agents that use E3 ligases to induce degradation of specified drug targets. Gilead has an option to license drug candidates resulting from the work, and Nurix retains co-development and co-detail options on up to two programs in the United States, subject to certain restrictions.